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Background: Pseudomonas aeruginosa (PA) infection is involved in various lung diseases such as cystic fibrosis and
chronic obstructive pulmonary disease. However, treatment of PA infection is not very effective in part due to
antibiotic resistance. α1-antitrypsin (A1AT) has been shown to reduce PA infection in humans and animals, but the
underlying mechanisms remain unclear. The goal of our study is to test whether a novel endogenous host defense
protein, short palate, lung, and nasal epithelium clone 1 (SPLUNC1), is involved in the therapeutic effect of A1AT
during lung PA infection.
Method: SPLUNC1 knockout (KO) and littermate wild-type (WT) mice on the C57BL/6 background were intranasally
infected with PA to determine the therapeutic effects of A1AT. A1AT was aerosolized to mice 2 hrs after the PA
infection, and mice were sacrificed 24 hrs later. PA load and inflammation were quantified in the lung, and
SPLUNC1 protein in bronchoalveolar lavage (BAL) fluid was examined by Western blot.
Results: In WT mice, PA infection significantly increased neutrophil elastase (NE) activity, but reduced SPLUNC1
protein in BAL fluid. Notably, PA-infected mice treated with A1AT versus bovine serum albumin (BSA) demonstrated
higher levels of SPLUNC1 protein expression, which are accompanied by lower levels of NE activity, lung bacterial load,
and pro-inflammatory cytokine production. To determine whether A1AT therapeutic effects are dependent on
SPLUNC1, lung PA load in A1AT- or BSA-treated SPLUNC1 KO mice was examined. Unlike the WT mice, A1AT treatment
in SPLUNC1 KO mice had no significant impact on lung PA load and pro-inflammatory cytokine production.
Conclusion: A1AT reduces lung bacterial infection in mice in part by preventing NE-mediated SPLUNC1 degradation.
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Bacterial infection is involved in the pathogenesis of cystic
fibrosis (CF) and chronic obstructive pulmonary disease
(COPD) [1]. Persistent lung Pseudomonas aeruginosa (PA)
infection is one the most common causes associated with
the exacerbations of CF and COPD [1-3]. One of the major
challenges in the treatment of PA infection is the rising
antibiotic resistance [4]. A previous study has demonstrated
the therapeutic effect of α1-antitrypsin (A1AT) against PA
infection in CF patients [5]. Animal studies also suggested* Correspondence: ChuHw@NJHealth.org
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reproduction in any medium, provided the orthe anti-PA effects of A1AT [5,6], but how A1AT improves
host defense against PA infection remains unknown.
PA infection in the lung elicits a robust inflammatory re-
sponse such as recruitment and activation of neutrophils.
Neutrophil elastase (NE) is released during lung inflam-
mation, which in turn may cause detrimental effects
such as tissue destruction seen in emphysema. We have
demonstrated that human NE (HNE) impairs airway
epithelial defense functions against bacterial infections
by degrading short palate, lung, and nasal epithelium
clone 1 (SPLUNC1) protein [7]. SPLUNC1 is a 25-kDa
secretory protein from large airway epithelial cells.
It has been shown to exert host defense function
against several strains of bacteria including PA, non-
typeable Haemophilus influenzae (NTHi) and Mycoplasmatd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SPLUNC1 and subsequently impair lung defense against
PA infection has not been investigated.
A1AT is a 52-kDa serine protease inhibitor mainly pro-
duced by the liver and in the lung by macrophages and
epithelial cells. In the lung, A1AT is a potent inhibitor of
neutrophil elastase protecting the lung tissue from proteo-
lytic degradation [10]. In individuals with a genetic defi-
ciency of A1AT there is an imbalance between neutrophil
elastase and A1AT in the lung increasing the risk of deve-
loping emphysema [11]. Purified human A1AT has been
used to treat A1AT deficiency by augmenting A1AT levels
and inhibiting NE activity [12,13]. In the current study, we
hypothesized that A1AT prevents NE-mediated SPLUNC1
degradation and subsequently enhances lung defense
against PA infection. To test our hypothesis, we utilized
the PA infection model in wild-type and SPLUNC1 knock-
out (KO) mice with or without A1AT treatment. First, we
confirmed that PA infection reduces SPLUNC1 expression
in mouse bronchoalveolar lavage (BAL) fluid. Second, we
demonstrated that A1AT increased SPLUNC1 levels in
PA-infected wild-type mice, and decreased lung PA load.
Third, we found that SLPUNC1 is required to improve
lung defense against PA.
Methods
Animals
SPLUNC1 knockout (KO) and littermate control wild-
type (WT) mice on the C57BL/6 background were used
for the current study. SPLUNC1 KO mice were gener-
ated as we previously reported [14]. All mice were bred
and housed in our biological resource center under
pathogen-free conditions, and tested to establish that
they were virus and M. pulmonis free. All the animal
procedures were approved by the IACUC at National
Jewish Health.
Pseudomonas aeruginosa culture
Pseudomonas aeruginosa (PA) strain PAO1 was kindly
provided by Dr. Michael Schurr at the University of
Colorado Denver, and was stored at −80°C. For each ex-
periment, bacteria were first streaked onto a Tryptic-Soy
agar plate and cultured for 18–22 hrs at 37°C. An indi-
vidual colony was then inoculated into Tryptic-Soy
medium and shaked at 37°C to grow the bacteria until
1 × 108 CFUs/ml were achieved as determined by spec-
trophotometry (optical density at 600 nm = 0.5).
Mouse model of PA infection with α1-antitrypsin treatment
PA (1.5 × 107 CFUs/mouse in 30 μl saline) or saline (con-
trol) was intranasally inoculated to WT and SPLUNC1
KO mice. After 2 hrs of PA infection, purified human
alpha-1 proteinase inhibitor (A1AT or Prolastin-C, Grifols
Inc., Research Triangle Park, NC) or bovine serumalbumin (BSA, Sigma-Aldrich, as the A1AT control) were
aerosolized to mice. To deliver A1AT or BSA, WT and
SPLUNC1 KO mice were placed in a Plexiglas chamber
and treated with aerosolized A1AT or BSA (0.5 mg/ml,
total volume = 10 ml) for 30 minutes by using an ultra-
sonic nebulizer (De Vilbiss) at an airflow rate of 8 L/min.
After 24 hrs of PA infection, lung lavage was performed
to collect bronchoalveolar lavage (BAL) fluid for cell
count, and measurement of KC and NE activity.
BAL and lung tissue processing
Mouse lungs were lavaged with 1 ml of sterile saline.
Cell-free BAL fluid were stored at −80°C for cytokine
analysis and Western blot. Cytospins of BAL cells were
stained with a Diff-Quick Kit (IMEB INC., San Marcos,
CA), and leukocyte differentials were determined as
percentage of 500 counted leukocytes. The left lung
lobe from infected mice was homogenized in PBS, the
homogenates were then cultured on Tryptic-Soy agar
plates to quantify PA levels.
Western blot analysis of mouse SPLUNC1 protein
Western blot analysis was carried out to quantify
SPLUNC1 protein. In brief, 30 μl BAL fluid was elec-
trophoresed on 10% SDS-polyacrylamide gel electrophor-
esis, transferred onto a nitrocellulose membrane, blocked
with the Western blocking buffer, and incubated with a
sheep anti-mouse SPLUNC1 antibody (R&D Systems,
Inc., Minneapolis, MN) overnight at 4°C. After washes in
PBS with 0.1% Tween 20, the membranes were incubated
with an anti-sheep IgG conjugated to horseradish perox-
idase. Membranes were stained with Ponceau S solution
to normalize total protein load by comparing the 68-kDa
protein (corresponding to albumin) levels. Densitometry
was performed using the NIH Image-J software. The ratio
of SPLUNC1/albumin was used to normalize SPLUNC1
protein expression in BAL fluid.
ELISA of mouse KC
KC, a homolog of human IL-8, in mouse BAL fluid was
determined by using a mouse KC DuoSet ELISA Devel-
opment kit (R&D Systems, Minneapolis, MN) as per
manufacturer’s instruction.
Neutrophil elastase (NE) activity assay in mouse BAL fluid
NE activity in mouse BAL fluid samples was measured
using the substrate N-(methoxysuccinyl)-Ala-Ala-Pro-Val
p-nitroanilide (Sigma-Aldrich) [15]. The samples were
mixed with an equal volume of 0.1 M HEPES buffer con-
taining 0.5 mmol/L NaCl (pH 7.5), and then transferred
to a 96-well plate. Saline solution mixed with NaCl/
HEPES buffer was used as a negative control. The sub-
strate, 2 mmol/L N-(methoxysuccinyl)-Ala-Ala-Pro-Val





























Figure 1 Pseudomonas aeruginosa (PA) infection reduces
SPLUNC1 and increases neutrophil elastase (NE) activity in
bronchoalveolar lavage (BAL) fluid of wild-type (WT) mice.
BAL fluid from WT mice was processed for SPLUNC1 protein
Western blot. (A) – Quantitative analysis of BAL fluid SPLUNC1
protein expression normalized by albumin. (B) – Representative
Western blot image of SPLUNC1 and albumin. The vertical dotted
red line separates the saline group from the PA infection group.
The two lanes under saline or PA treatment represent SPLUNC1 data
from two different mice. (C) – NE activity was examined by an NE
activity assay as described in Materials and methods. N = 4 – 5 mice
per group. Data are expressed as means ± SEM.
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405 nm using a spectrophotometer. The OD readings
were used to reflect NE activity.
Statistical analysis
Data are presented as means ± SEM. One-way analysis of
variance (ANOVA) was used for multiple comparisons,
and a Tukey’s post hoc test was applied to illustrate the
significant differences between two groups. Student’s t test
was used when only two groups were compared. A p
value < 0.05 was considered significant.
Results
Reduced SPLUNC1, but increased NE activity in BAL fluid
of PA-infected wild-type mice
After 24 hrs of PA infection in wild-type mice, SPLUNC1
protein in BAL fluid was examined by Western blot ana-
lysis. As shown in Figure 1A and 1B, PA infection reduced
SPLUNC1 protein expression in BAL fluid. In contrast to
the SPLUNC1 data, NE activity was significantly increased
after the PA infection (Figure 1C).
Therapeutic effect of A1AT on lung SPLUNC1, NE activity,
bacterial load and inflammation in wild-type mice
To determine whether A1AT restores SPLUNC1 levels
in PA-infected mouse lungs, A1AT was aerosolized to
mice 2 hrs after an intranasal inoculation of PA. After
24 hrs of PA infection, A1AT treatment significantly in-
creased SPLUNC1 protein levels in BAL fluid as com-
pared to BSA treatment (Figure 2A and 2B). In line with
the SPLUNC1 data, NE activity was reduced following
A1AT treatment (Figure 2C).
Notably, the PA load was reduced by A1AT treatment
(Figure 3). Likewise, A1AT significantly reduced PA
infection-induced KC (Figure 4A) and trended to reduce
total leukocytes (Figure 4B) in BAL fluid. However, the
total number of neutrophils in BAL fluid was not signifi-
cantly reduced by A1AT (Figure 4C).
No therapeutic effect of A1AT on lung bacterial load and
inflammation in SPLUNC1 KO mice
To determine if the therapeutic effect of A1AT is
dependent on SPLUNC1, PA-infected SPLUNC1 KO
mice were treated with A1AT or BSA. Unlike the WT
mice, SPLUNC1 KO mice, following the A1AT treat-
ment, failed to decrease lung PA load and inflammation
(Figure 5A and 5B).
Discussion
The current study provides a novel mechanism by which
A1AT exerts host defense function against lung PA infec-
tion. By using a SPLUNC1 KO mouse model, we were
able to reveal a critical role of SPLUNC1 in A1AT-
mediated host defense function. First, PA infectionsignificantly reduced SPLUNC1 expression in wild-type
mice, which was accompanied by increased NE activity.
Second, A1AT treatment significantly reduced lung PA
load and inflammation in wild-type mice, but not in
SPLUNC1 KO mice.
Persistent lung PA infection is a significant challenge
in the management of CF and COPD patients, particu-











Figure 2 A1AT treatment enhances SPLUNC1 and reduces NE
activity in bronchoalveolar lavage (BAL) fluid of PA-infected WT
mice. PA-infected mice were treated with A1AT for 22 hrs and
sacrificed after 24 hrs of infection as described in Materials and Methods.
Quantitative analysis (A) and representative image (B) of BAL fluid
SPLUNC1 Western blot were shown to demonstrate the therapeutic
effect of A1AT treatment. The two lanes of Western blot image under
saline or PA treatment represent SPLUNC1 data from two different mice.
NE activity (C) was examined by an NE activity assay. N = 4 – 7 mice per
group. The vertical dotted red line in Figure 2B separates the saline
group from the PA infection group. NS indicates no significant differ-




























Figure 3 A1AT treatment reduces lung PA load in wild-type
(WT) mice. Left lungs from PA-infected WT mice were homogenized,
and PA load was quantified by culture. The horizontal solid red lines
indicate medians of CFUs.
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release of various mediators such as NE that degrades
proteins (e.g., elastin, fibronectin), leading to disease pro-
gression [7,16]. Although previous studies suggest a the-
rapeutic role of A1AT, an inhibitor of NE, in host defenseagainst bacterial (e.g., PA) infection in vivo [6], the under-
lying mechanisms remain poorly understood. We and
others have previously demonstrated that SPLUNC1 exerts
host defense function against bacterial infection [7-9], and
HNE can degrade secreted SPLUNC1 from airway epithe-
lial cells [7]. We clearly showed that A1AT is effective in
reducing PA load in wild-type mice, but not in SPLUNC1
KO mice. Our results suggest that SPLUNC1 is critical to
A1AT-mediated host defense function against PA infection.
The impact of an in vivo PA infection on SPLUNC1
expression is unclear. Bingle and co-workers have found
increased SPLUNC1 protein expression by airway epi-
thelial cells of CF patients [17]. However, this study did
not measure the levels of released SPLUNC1 in the air-
way lumen, and the association of SPLUNC1 levels with
NE levels. To clarify the role of an in vivo PA infection
on SPLUNC1 levels, we examined SPLUNC1 protein in
BAL fluid of PA-infected mice. We, for the first time,
demonstrated that PA infection reduces SPLUNC1 pro-
tein in mouse BAL fluid. The reduced SPLUNC1 may be
in part explained by increased NE activity following PA
infection as we have shown SPLUNC1 degradation by
NE [7]. Additionally, PA-derived elastase may contribute
to SPLUNC1 reduction in BAL fluid because it has been
shown to degrade some innate immunity components
(e.g., surfactant protein A) [18]. We speculate that dur-
ing PA infection, airway epithelial cells increase intracel-
lular SPLUNC1 expression to compensate the loss of
secreted SPLUNC1 due to its degradation by proteases
including NE. Although we have shown SPLUNC1
up-regulation by an atypical bacterium Mycoplasma




































































Figure 4 A1AT treatment reduces PA-induced KC level and
trend to reduce total leukocytes in BAL fluid of wild-type (WT)
mice. (A) – KC; (B) – total leukocytes; and (C) – BAL neutrophils;
N = 4 – 7 mice per group. NS indicates no significant differences.



























Figure 5 A1AT treatment does not reduce lung PA load and
inflammation in SPLUNC1 knockout (KO) mice. (A) – PA load
was quantified in homogenized left lungs. The horizontal solid red
lines indicate medians of CFUs. (B) – KC levels were quantified by
using an ELISA. N = 4 – 7 mice per group. NS indicates no significant
differences. Data are expressed as means ± SEM.
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warrants future study.
One of our major research questions is about whether
A1AT can rescue PA infection-induced SPLUNC1 reduc-
tion and subsequently enhance host defense against PAinfection. To address this question, A1AT was aerosolized
to mice 2 hrs after PA infection. This therapeutic ap-
proach clearly demonstrated that A1AT treatment re-
stored SPLUNC1 levels in BAL fluid of wild-type mice,
which was accompanied by reduced NE activity. Our
results have suggested an in vivo mechanism of A1AT
function. To further demonstrate the role of SPLUNC1 in
A1AT therapeutic effect, we treated PA-infected SPLUNC1
KO mice with A1AT. Unlike the wild-type mice, SPLUNC1
KO mice did not show reduced lung PA load. These results
emphasize that A1AT therapeutic effect during PA infec-
tion depends on SPLUNC1. Given the fact that A1AT can
enter into the cells, it would be interesting to determine
whether it has a direct effect on intracellular SPLUNC1
mRNA or protein expression. In our primary normal hu-
man airway epithelial cell culture experiments, we found
that A1AT has no direct effects on intracellular SPLUNC1
AB
Figure 6 A1AT pre-treatment reduces lung PA load in wild-type
(WT) mice, but not in SPLUNC1 knockout (KO) mice. WT and
SPLUNC1 KO mice were treated with aerosolized A1AT (0.5 mg/ml).
Two hours later, mice were intranasally infected with PA (1.5 × 107
CFUs/mouse). After 24 hrs of PA infection, lung tissues were
processed to quantify PA load. While A1AT significantly reduced
lung PA load in WT mice (A), it did not alter the PA load in
SPLUNC1 KO mice (B). N = 4 – 5 mice per group. The horizontal
solid red lines indicate medians of CFUs.
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preventing extracellular SPLUNC1 protein from degrad-
ation by NE and perhaps other proteases.
We found that lung pro-inflammatory cytokine KC
was significantly reduced by A1AT in PA-infected
wild-type mouse lungs. However, leukocytes including
neutrophils were not as significantly reduced as KC.
This may be explained by several factors. First, we only
gave one dose of A1AT treatment in PA-infected mice.
As a previous study demonstrated a significant inhib-
ition of lung neutrophils following repeated A1AT
treatments in cigarette smoke-exposed mice [20], we
may need to deliver A1AT multiple times (e.g., before
and after PA infection) to markedly suppress lung neu-
trophil recruitment. Second, A1AT has diverse NE-
dependent and NE-independent functions [21]. Lastly,
leukocyte numbers may not reflect cell activity. Future
studies will explore the direct effects of A1AT on in-
flammatory cell functions.
We realize that SPLUNC1 KO mice demonstrated
greater variability of PA load in the lung than the wild-
type mice although the sample size of SPLUNC1 KO
and wild-type mice is similar. Thus, it appears that
bacterial load variability in our current study is related
to the genetic background. We confirmed such greater
variability of lung bacterial load in SPLUNC1 KO mice
that were pre-treated with A1AT and then infected
with PA. We found that A1AT aerosolized 2 hrs prior
to PA infection decreased lung PA load in wild-type
mice, but not in SPLUNC1 KO mice (Figure 6).
There are several limitations to our current study.
First, only one strain of bacteria (i.e., PA) was used in
our study. Future studies using other strains of bac-
teria (e.g., NTHi) are warranted to examine the broad-
spectrum effect of A1AT against lung infection. Second,
an acute (e.g., 24 hr) PA infection model was carried
out to address our research questions. Although we
were able to demonstrate a critical role of SPLUNC1
in A1AT-mediated host defense against PA infection
with an acute model, a chronic infection model will
certainly be beneficial to study the role of SPLUNC1
in disease progression. Lastly, to increase the relevance
of our animal research findings to patients, we plan to
measure SPLUNC1 and PA in sputum and BAL sam-
ples from CF and COPD patients treated with A1AT
or placebo.Conclusion
Our current study has provided a novel mechanism
underlying A1AT-mediated host defense against bacter-
ial infection. Our research findings indicate that A1AT
exerts host defense functions against PA infection in part
by modulating the host defense protein SPLUNC1.Abbreviations
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WT: Wild-type.
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